Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Targeting prostate cancer stem-like cells by an immunotherapeutic platform based on immunogenic peptide-sensitized dendritic cells-cytokine-induced killer cells

Fig. 6

Cytotoxicity or cancer cell killing efficiency of peptide-loaded DC-activated CIK cells against the prostatospheroid-derived prostate cancer cells as determined by CCK-8 cell viability assay followed by A450 measurement. Results showed that the peptide-loaded P-DC-CIK cells exhibited significantly higher cancer cell killing efficiency against the prostate cancer cells derived from DU145, LNCaP, or VCaP prostatospheroids than the peptide-unloaded NP-DC-CIK cells (control). No significant difference on the cytotoxicity against the prostate cancer cells was observed among the different EpCAM- and CD44-derived peptides (P1, P2, and P3) and also between effect-target ratios of 5:1 and 10:1. *P < 0.05; **P < 0.01 versus peptide-unloaded NP-DC-CIK cells

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512